These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

700 related items for PubMed ID: 21163071

  • 1. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
    Guo GF, Xia LP, Qiu HJ, Xu RH, Zhang B, Jiang WQ, Zhou FF, Wang F.
    Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
    [Abstract] [Full Text] [Related]

  • 2. [Efficacy of cetuximab combined with chemotherapy on advanced colorectal cancer: a report of 53 cases].
    Guo GF, Xia LP, Zhang B, Jiang WQ, Liu MZ, Hu PL, Chen XX, Qiu HJ, Zhou FF.
    Ai Zheng; 2009 Dec; 28(12):1317-23. PubMed ID: 19958628
    [Abstract] [Full Text] [Related]

  • 3. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
    Guo X, Liu TS, Yu YY, Zhou YH, Chen Y, Zhuang RY, Cui YH.
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
    [Abstract] [Full Text] [Related]

  • 4. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V.
    J Clin Oncol; 2011 Mar 10; 29(8):1050-8. PubMed ID: 21300933
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
    Luo HY, Li YH, Zhang L, Jiang WQ, Shi YX, Wang F, He YJ, Xu RH.
    Ai Zheng; 2007 Aug 10; 26(8):905-8. PubMed ID: 17697557
    [Abstract] [Full Text] [Related]

  • 6. [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
    Lin L, Xu JM, Wang Y, Ge FJ, Liu LJ, Zhao CH, Li SS, Liu JZ, Li ZQ.
    Zhonghua Zhong Liu Za Zhi; 2010 Oct 10; 32(10):786-90. PubMed ID: 21163073
    [Abstract] [Full Text] [Related]

  • 7. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY.
    Clin Colorectal Cancer; 2012 Mar 10; 11(1):38-44. PubMed ID: 21803002
    [Abstract] [Full Text] [Related]

  • 8. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
    Carneiro BA, Ramanathan RK, Fakih MG, Krishnamurthi SS, Lembersky BC, Stoller RG, Lancaster SL, Pinkerton RA, Crandall TL, Schmotzer AR, Potter DM, Bahary N.
    Clin Colorectal Cancer; 2012 Mar 10; 11(1):53-9. PubMed ID: 21813336
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
    Li YH, Wang FH, Zhang DS, Wang ZQ, Feng F, Zhang L, Xu RH, Jiang WQ, He YJ.
    Ai Zheng; 2009 Sep 10; 28(9):913-8. PubMed ID: 19728906
    [Abstract] [Full Text] [Related]

  • 10. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
    Fornaro L, Vasile E, Masi G, Loupakis F, Baldi GG, Allegrini G, Salvatore L, Cremolini C, Cupini S, Cortesi E, Tuzi A, Granetto C, Brunetti IM, Ricci S, Falcone A.
    Clin Colorectal Cancer; 2012 Mar 10; 11(1):71-6. PubMed ID: 21903485
    [Abstract] [Full Text] [Related]

  • 11. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
    Spigel DR, Greco FA, Waterhouse D, Shipley D, Lane CM, Vazquez ER, Clark BL, Infante JR, Bendell JC, Burris HA, Hainsworth JD.
    Clin Adv Hematol Oncol; 2010 Jul 10; 8(7):480-5, 498. PubMed ID: 20864916
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
    Zhang X, Wu Y, Gong J, Lu Z, Zhou J, Wang X, Lu M, Li J, Cao Y, Li Y, Li J, Shen L.
    Zhonghua Zhong Liu Za Zhi; 2014 Mar 10; 36(3):223-7. PubMed ID: 24785285
    [Abstract] [Full Text] [Related]

  • 14. [Correlation analysis between abundance of K-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer].
    Bai YQ, Liu XJ, Wang Y, Ge FJ, Zhao CH, Fu YL, Lin L, Xu JM.
    Zhonghua Zhong Liu Za Zhi; 2013 Sep 10; 35(9):666-71. PubMed ID: 24332053
    [Abstract] [Full Text] [Related]

  • 15. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV, Cosgriff TM, Headley DL, Badarinath S, Dakhil SR.
    Clin Colorectal Cancer; 2010 Apr 10; 9(2):102-7. PubMed ID: 20378504
    [Abstract] [Full Text] [Related]

  • 16. [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
    Li J, Xu JM, Li J, Zhang XD, Bai Y, Chu YP, Wang YH, Liu DQ, Jin ML, Shen L.
    Zhonghua Zhong Liu Za Zhi; 2008 Mar 10; 30(3):225-7. PubMed ID: 18756942
    [Abstract] [Full Text] [Related]

  • 17. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
    Fischer von Weikersthal L, Schalhorn A, Stauch M, Quietzsch D, Maubach PA, Lambertz H, Oruzio D, Schlag R, Weigang-Köhler K, Vehling-Kaiser U, Schulze M, Truckenbrodt J, Goebeler M, Mittermüller J, Bosse D, Szukics B, Grundeis M, Zwingers T, Giessen C, Heinemann V.
    Eur J Cancer; 2011 Jan 10; 47(2):206-14. PubMed ID: 20971632
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
    Souglakos J, Kalykaki A, Vamvakas L, Androulakis N, Kalbakis K, Agelaki S, Vardakis N, Tzardi M, Kotsakis AP, Gioulbasanis J, Tsetis D, Sfakiotaki G, Chatzidaki D, Mavroudis D, Georgoulias V.
    Ann Oncol; 2007 Feb 10; 18(2):305-10. PubMed ID: 17079693
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
    Brodowicz T, Ciuleanu TE, Radosavljevic D, Shacham-Shmueli E, Vrbanec D, Plate S, Mrsic-Krmpotic Z, Dank M, Purkalne G, Messinger D, Zielinski CC.
    Ann Oncol; 2013 Jul 10; 24(7):1769-1777. PubMed ID: 23559149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.